Abstract:Abstract BACKGROUND Time is a crucial component in all diagnostic and therapeutic processes of cancer. Retard in the treatment can have adverse consequences on outcomes. Total treatment delays could be due to patient interval (from the first perceived symptom to the first medical consultation) and system interval (from the first medical consultation to end of treatment). To minimize delays, it is essential to know the time intervals elapsed between each of the steps in the diagnostic and the treatment phase.The purpose of this pilot study is to holistically analyze the total treatment interval of cancer patients as a part of process-oriented total quality management with the ultimate intention of having more useful information for benchmarking and making decisions to improve time in oncology. MATERIAL AND METHODS During 2019 in a context of public health-care system all relevant clinical pathway time data from the patient’s perceived first symptom until the end of oncological treatment were collected in a prospective cohort of newly diagnosed glioblastoma patients. Clinical pathway is defined as a description of the current practice in an homogeneous patient group treated by a multidisciplinary team and an inventory of actions defining a diagnostic and therapeutic sequence. This cohort was compared with a serie of glioblastoma patients treated in 2020 (COVID-19-year). We analyzed the mean, median and quartile data of 16-time intervals represented on a time scale RESULTS From January 1 to December 31, 2019, we collected data from 59 patients diagnosed and treated for a glioblastoma. There were 24 women and 35 men with a mean age of 60,9 years. We collected 1062 time-points. This group was compared with a COVID-19-year cohort of 49 patients (14 women and 35 men with a mean age of 61,7 years and 630 time-points). The median patient interval time and the system interval time were 6 days (0-210) vs 5 (0-150) and 240 days (81-363) vs 255 (120-482) respectively. Median time from surgery to the start of adjuvancy was 34 days (19-56) vs 34 (17-108). No differences were found in any of the intervals analyzed, in the overall treatment time of radiotherapy or in the dose intensity of chemotherapy. CONCLUSION The routine measurement of the intervals between the different diagnostic and therapeutic actions is essential to monitor the time of clinical processes in terms of quality and benchmarking. It is also essential to standardize in a holistic way the distressing temporality in oncology.

The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients

Nature and impact of symptoms at time of initial presentation for patients with glioblastoma

Survival Impact of Delaying Postoperative Chemoradiotherapy in Newly Diagnosed High-Grade Glioma Patients

P21.06.A TIME IN ONCOLOGY. GLIOBLASTOMA REAL-WORLD DATA

Significance of radiation therapy in frontal glioblastoma patients and exploration of optimal treatment modality: a real-world multiple-center study based on propensity score matching

The Influence of Danish Cancer Patient Pathways on Survival in Deep-Seated, High-Grade Soft-Tissue Sarcomas in the Extremities and Trunk Wall: A Retrospective Observational Study

Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study

Therapy Intensity Outweighs the Prognostic Importance of the Timing of Chemoradiotherapy in Newly Diagnosed Glioblastoma Patients

The Impact of the COVID-19 Pandemic and Lockdown on the Outcome of Glioblastoma

The impact of brain cancer care coordinators on healthcare utilization and outcomes in patients with glioblastoma

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

Glioblastoma Therapy: Past, Present and Future

Prognosis of glioblastoma patients improves significantly over time interrogating historical controls

Unravelling the Impact of Tumor Location on Patient Survival in Glioblastoma: A Genomics and Radiomics Approach

Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study

Impact of genomic background and developmental state on signaling pathways and response to therapy in Glioblastoma patient-derived cells

Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis

Survival Determinants in Glioblastoma: An Insight into Biopsy-Only Patient Outcomes

Clinical Features Associated with the Efficacy of Chemotherapy in Patients with Glioblastoma (GBM): A Population-based Study

Epid-18. Patterns Of Care And Clinical Outcomes Of Patients With Glioblastoma From 2005-2020: A Real-World Analysis

Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial